Key points are not available for this paper at this time.
Neoadjuvant treatment appears to improve overall survival by intention to treat, despite lower overall resection rates for resectable or borderline resectable pancreatic cancer. PROSPERO registration number: CRD42016049374.
Versteijne et al. (Mon,) studied this question.